相关实验视频

Updated: Jun 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

评估EGFR突变的NSCLC与骨转移:临床特征和最佳治疗策略

Wei-Chun Chen^1,2,3,4,5, Wen-Chien Cheng^1,2,3,4,5, Chieh-Lung Chen¹

¹Division of Pulmonary and Critical Care, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

Cancer medicine

|March 29, 2024

概括

骨转移 (BoM) 是EGFR突变非小细胞肺癌 (NSCLC) 的负预后因素. 添加抗血管新生疗法 (AAT),denosumab和顺序性 osimertinib 改善了这些患者的生存结果.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

研究患有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 患者骨转移 (BoM) 的临床特征.
确定EGFR突变NSCLC与BoM的最佳治疗策略,使用EGFR-氨酸激酶抑制剂 (TKI).

研究的目的:

检查EGFR突变NSCLC中的BoM的临床特征.
为了确定这个患者群体最有效的治疗策略.

主要方法:

对247名患有EGFR突变NSCLC第4期EGFR突变NSCLC的患者进行了回顾性分析,这些患者接受了第一线EGFR-TKIs (2014年1月至2020年12月).
患者被分为诊断时有或没有BoM的组;根据denosumab使用情况进一步分析BoM组.
多变量考克斯回归用于确定影响整体存活时间 (OS) 的因素.

主要成果:

BoM的存在与较短的无进展生存期和OS相关 (p=0.002).
在 BoM 组中观察到额外胸部转移的更高发病率 (p<0.001).
顺序性奥西默蒂尼布,抗血管生成疗法 (AAT) 和代诺苏马布显著改善了BoM患者的OS.

结论:

BoM是EGFR突变NSCLC的负预后指标,可能与胸外转移有关.
组合疗法包括连续的奥西默蒂尼布,AAT和登苏马布可以提高患有BoM的NSCLC患者的存活率.

关键词:

抗血管生成是一种反血管生成.骨转移的发生.化疗化疗是一种化学疗法.这里没有denosumab.皮肤上生长因子受体.氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...